| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $47.1M | -40.1% |
| Cost of Revenue | $47.1M | -40.1% |
| R&D Expense | $240.2M | +27.1% |
| SG&A Expense | $63.5M | +15.4% |
| Operating Income | -$261.6M | -58.1% |
| Net Income | -$223.9M | -52.3% |
| EPS (Basic) | -$2.98 | -18.3% |
| EPS (Diluted) | -$2.98 | -18.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $120.3M | +9.4% |
| Accounts Receivable | $0 | -100.0% |
| Current Assets | $510.3M | +25.9% |
| Total Assets | $978.0M | +69.9% |
| Current Liabilities | $67.8M | -20.9% |
| Total Liabilities | $142.4M | -21.2% |
| Stockholders' Equity | $835.6M | +111.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$194.5M | -89.2% |
| Capital Expenditures | $12.8M | -62.8% |
| Investing Cash Flow | -$404.1M | -388.9% |
| Financing Cash Flow | $608.9M | — |
| Free Cash Flow | -$207.3M | -51.0% |